Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Email

Triptorelin Pamoate

Placeholder slot
 (TRIP-toh-REH-lin PAM-oh-ayt)

Triptorelin works by first signaling the pituitary gland to release more luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which briefly raises testosterone levels. With continued use, the pituitary gland stops making as much LH and FSH, leading to lower testosterone levels over time. This helps slow or stop the growth of cancer cells that need testosterone to grow. It is a type of luteinizing hormone-releasing hormone (LHRH) agonist.

US Brand Name(s)
Trelstar
Trelstar Depot
FDA Approved
Yes

FDA label information for this drug is available at DailyMed.

Use in Cancer

Triptorelin pamoate is approved to treat prostate cancer that is advanced.

Triptorelin pamoate is also being studied in the treatment of other types of cancer.

More About Triptorelin Pamoate

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

Research Results and Related Resources

Hormone Therapy for Prostate Cancer

Clinical Trials Accepting Patients

Find Clinical Trials for Triptorelin Pamoate - Check for trials from NCI's list of cancer clinical trials now accepting patients.

  • Posted:
  • Updated:
Email